News

Nanobiotix inks US$56m deal
Enlarge image

BusinessFrance

Nanobiotix inks US$56m deal

07.08.2012 - In a deal worth $56m, Nanobiotix S.A. has entered into an exclusive partnership with PharmaEngine, Inc. for the rapid development of NBTXR3, a novel cancer nanotherapeutic.

With the partnership the Paris-based developer of the nanoparticle cancer radiotherapy booster NBTXR3 will speed up the global clinical development of its compound that is currently tested in a Phase I pilot study as treatment for soft tissue sarcoma. PharmaEngine will add its Asia-based complementary clinical development strengths and will conduct further clinical studies.

Under the terms of the agreement, Taiwanese PharmaEngine will receive exclusive rights to develop and commercialize NBTXR3 in the Asian-Pacific region, including Australia, China, India, Japan, Korea, Taiwan and other countries, while Nanobiotix retains exclusive rights for the rest of the world. Nanobiotix retains an option to re-acquire the rights for the entire Asian-Pacific territory except for China and Taiwan, according to pre-defined conditions in exchange for termination payments and agreed-upon royalties.

Nanobiotix will receive an initial upfront payment of US$ 1 million and commercialisation milestone payments of up to US$56m plus tiered, double-digit royalties on net product sales in the Asian-Pacific region. PharmaEngine will further fund the clinical development of NBTXR3 in three different indications with the goal to commence clinical studies in two indications within the next 18 months. The parties have agreed to share the data to enable an efficient and focused global development in multiple indications.

NBTXR3 is a nanoparticle formulation of hafnium oxide crystals for the local treatment of tumours to enhance the efficacy of radiotherapy. In a mouse model NBTRX tripled the generation of free radicals, thus NanoXray particles could change the clinical outcome. Taipei-based PharmaEngine adopts the business model of “no research, development only” and focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M&AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M&ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

M&AFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

BioeconomyBelgiumUK

30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.

ConventionEUUK

25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.

InvestmentGermanyNetherlands

24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.

InvestmentNetherlands

20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • FLAMEL TECHNOLOGIES (F)14.70 USD11.28%
  • SERODUS (N)3.05 NOK7.02%
  • ADDEX (CH)4.54 CHF5.83%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.48 EUR-10.04%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.43 EUR102.0%

FLOP

  • THROMBOGENICS (B)8.67 EUR-51.3%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.67 EUR-73.1%

No liability assumed, Date: 11.07.2014